Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

RAs are transforming obesity treatment, demonstrating substantial weight loss and metabolic improvements with lifestyle ...

Bengaluru: Biocon Limited, an innovation-led global biopharmaceutical company, has announced the launch of its GLP-1 peptide, ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...